Literature DB >> 19277723

Radiological imaging change in a malignant bowel obstruction patient treated with octreotide.

Takuya Shinjo1, Ryogo Kagami.   

Abstract

INTRODUCTION: Malignant bowel obstruction (MBO) is a complication in advanced cancer patients with abdominal and pelvic malignancy. Recent research has established the efficacy of octreotide for MBO-related symptom relief. The mechanism that octreotide increases water absorption in case of MBO has not been demonstrated except for experimental animal and normal human model. CASE REPORT: We present a 60-year-old man with pancreatic cancer and MBO treated with octreotide. Radiological imaging showed the disappearance of large-volume fluid retention in the small intestine with alleviating vomiting within 2 days. This radiological change might result from the effect of octreotide increasing water absorption in intestine tract.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19277723     DOI: 10.1007/s00520-009-0608-4

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  10 in total

1.  Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial.

Authors:  C Ripamonti; S Mercadante; L Groff; E Zecca; F De Conno; A Casuccio
Journal:  J Pain Symptom Manage       Date:  2000-01       Impact factor: 3.612

2.  Improvement in the intestinal processes of hydroelectrolytic absorption and secretion in abdominal pathologies of surgical interest treated with SMS 201-995: experimental protocol.

Authors:  F F Guiró; G Bertolini; J V Salas
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

Review 3.  Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer.

Authors:  D J Feuer; K E Broadley
Journal:  Cochrane Database Syst Rev       Date:  2000

4.  Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction.

Authors:  S Mercadante; C Ripamonti; A Casuccio; E Zecca; L Groff
Journal:  Support Care Cancer       Date:  2000-05       Impact factor: 3.603

5.  The role of total parenteral nutrition for patients with irreversible bowel obstruction secondary to gynecological malignancy.

Authors:  J Philip; B Depczynski
Journal:  J Pain Symptom Manage       Date:  1997-02       Impact factor: 3.612

6.  Effect of octreotide on fluid absorption and secretion by the normal human jejunum and ileum in vivo.

Authors:  C Högenauer; B Aichbichler; C Santa Ana; J Porter; J Fordtran
Journal:  Aliment Pharmacol Ther       Date:  2002-04       Impact factor: 8.171

7.  Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial.

Authors:  Kyriaki Mystakidou; Eleni Tsilika; Ourania Kalaidopoulou; Kostas Chondros; Stavroula Georgaki; Lila Papadimitriou
Journal:  Anticancer Res       Date:  2002 Mar-Apr       Impact factor: 2.480

8.  Management of malignant bowel obstruction.

Authors:  Carla Ida Ripamonti; Alexandra M Easson; Hans Gerdes
Journal:  Eur J Cancer       Date:  2008-03-21       Impact factor: 9.162

Review 9.  Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review.

Authors:  Sebastiano Mercadante; Alessandra Casuccio; Salvatore Mangione
Journal:  J Pain Symptom Manage       Date:  2007-02       Impact factor: 3.612

Review 10.  Diarrhea in terminally ill patients: pathophysiology and treatment.

Authors:  S Mercadante
Journal:  J Pain Symptom Manage       Date:  1995-05       Impact factor: 3.612

  10 in total
  1 in total

1.  Surgical and Conservative Management of Malignant Bowel Obstruction: Outcome and Prognostic Factors.

Authors:  Kaiying Yu; Lihui Liu; Xiaowei Zhang; Zhanzhi Zhang; Benqiang Rao; Yongbing Chen; Suyun Li; Hanping Shi
Journal:  Cancer Manag Res       Date:  2020-08-24       Impact factor: 3.989

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.